Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
19,737,738
-
Share change
-
+1,701,367
-
Total reported value
-
$947,809,522
-
Price per share
-
$48.02
-
Number of holders
-
119
-
Value change
-
+$89,058,501
-
Number of buys
-
70
-
Number of sells
-
40
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q4 2022
As of 31 Dec 2022,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
119 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,737,738 shares.
The largest 10 holders included
FMR LLC, ORBIMED ADVISORS LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, STATE STREET CORP, Nantahala Capital Management, LLC, Candriam S.C.A., PRICE T ROWE ASSOCIATES INC /MD/, and First Light Asset Management, LLC.
This page lists
122
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.